PPCB:US
$6.64
18.996%
Propanc Biopharma IncNews & Events
Last updated: Jun 8, 2025, 8:12 PM ET
Propanc Biopharma's Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest
Business Wire AUG 21, 2024 9:00 AM EDTTwo Publications Reach 10 Citations & 4,500 Reads, Respectively Propanc Bioph...READ ARTICLEPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America
Business Wire AUG 14, 2024 9:00 AM EDTPatent Broadly Captures Both High Dose & High Ratio Claims for Future Clinical Doses of PRP A...READ ARTICLEPropanc Biopharma's CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
Business Wire JUL 17, 2024 9:00 AM EDTBritish Journal of Cancer Concludes Tumor cell-intrinsic PD-L1 function promotes EMT ...READ ARTICLEPropanc Biopharma Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office
Business Wire JUN 25, 2024 9:00 AM EDTCertificate of Grant Received for “Cancer Treatment” Patent from IP Corporation of ...READ ARTICLESidoti's November Micro-Cap Virtual Conference
ACCESS Newswire NOV 8, 2022 3:40 PM ESTPresentation Times and Weblinks Released for Over 35 Presenting Companies Wednesday an...READ ARTICLESeeThruEquity Issues Update on Propanc Biopharma, Inc.
ACCESS Newswire JUN 19, 2017 10:00 AM EDTNEW YORK, NY / ACCESSWIRE / June 19, 2017 / SeeThruEquity, a leading independent equity rese...READ ARTICLE